The Trump administration has reached a landmark agreement with Eli Lilly and Novo Nordisk to reduce prices for their popular weight-loss medications. In exchange, the pharmaceutical giants will receive tariff relief and expanded Medicare access. President Trump announced the deal from the Oval Office, highlighting his administration’s efforts to lower healthcare costs.
about Trump Cuts Drug Prices for Lilly, Novo in Tariff Deal
FinanceNews Article 
November 7, 2025 | 00:00
November 7, 2025 | 00:00
FinanceNews Article November 6, 2025 | 20:16
November 6, 2025 | 20:16
Novo Nordisk A/S
2 in Finance and 0 in Crypto last week
Lilly, Novo Cut Drug Prices for Medicare in Trump Deal
In a landmark pharmaceutical pricing agreement, Eli Lilly & Co. and Novo Nordisk A/S have secured deals with the Trump administration to significantly reduce prices for their blockbuster weight-loss drugs. The arrangement, announced Thursday at a White House event with President Donald Trump, provides the pharmaceutical giants with tariff relief in exchange for making these highly sought-after medications available to certain Medicare patients, representing a major shift in drug pricing policy and access for older Americans.
about Lilly, Novo Cut Drug Prices for Medicare in Trump DealTerry Smith Criticizes Danish Pharma Giants Novo, Coloplast
Terry Smith, the renowned fund manager often compared to Warren Buffett, has taken aim at Novo Nordisk and Coloplast, blaming the Danish life sciences giants for underperformance in his equity fund. His critique underscores broader concerns about these companies’ impact on investor portfolios. As a high-profile figure in finance, Smith’s comments could influence market sentiment toward these firms, particularly amid scrutiny of their financial health and growth prospects.
about Terry Smith Criticizes Danish Pharma Giants Novo, ColoplastPromising Value Stocks in Healthcare for Growth Through 2030
Pessimism in the healthcare sector has impacted stocks like Novo Nordisk and Pfizer, despite their strong growth prospects. Novo Nordisk faces production challenges for its popular GLP-1 drugs, while Pfizer is pivoting to oncology after a pandemic peak. Both companies are trading at bargain valuations, with significant earnings growth anticipated through 2030.
about Promising Value Stocks in Healthcare for Growth Through 2030European Stocks Expected to Lead Market Gains in 2025
In 2025, the stock market is predicted to gain between 15% to 25%, with European stocks leading the way, contrary to the S&P 500. This shift is driven by extreme pessimism among European investors, making them more sensitive to positive economic changes, while value stocks are expected to outperform growth stocks for the first time in years.
about European Stocks Expected to Lead Market Gains in 2025Stock Market Update: Futures Dip as Novo Nordisk Surges and Boeing Falls
U.S. stock futures are pointing lower after major indexes approached all-time highs. Novo Nordisk shares surged 14% following positive trial results for its weight-loss drug, while Boeing’s stock slipped over 1% due to a projected wider-than-expected loss. American Express reported Q4 results mostly in line with estimates, and Verizon exceeded expectations with strong subscriber growth.
about Stock Market Update: Futures Dip as Novo Nordisk Surges and Boeing FallsU.S. Stocks Retreat as Interest Rates Rise and Earnings Season Begins
U.S. stocks retreated from record highs, with the S&P 500 down 0.3% and the Dow Jones Industrial Average dipping 140 points. The bond market showed easing yields amid mixed economic data, while the Bank of Japan raised its benchmark interest rate to 0.5%, the highest since 2008. Notable stock movements included Texas Instruments falling 7.5% despite strong profits, while Novo Nordisk surged 8.5% on promising clinical trial results.
about U.S. Stocks Retreat as Interest Rates Rise and Earnings Season BeginsNew Study Highlights Benefits and Risks of Obesity Drugs Like Ozempic
A recent study published in Nature Medicine highlights the dual benefits and risks of obesity drugs like Ozempic and Mounjaro, showing they can lower the risk of diseases such as Alzheimer’s and heart disease while also posing risks like gastrointestinal issues and pancreatitis. Conducted by researchers from the U.S. Department of Veterans Affairs and Ewha Womans University, the study analyzed nearly 2 million medical records, revealing that these medications significantly impact health beyond weight loss. With obesity affecting nearly 42% of U.S. adults, the findings underscore the importance of discussing treatment options with healthcare providers.
about New Study Highlights Benefits and Risks of Obesity Drugs Like OzempicUS stocks rebound as inflation data shows signs of improvement
US stocks rebounded on Friday as inflation data indicated a slowdown in price increases for November, with the Dow Jones up 0.8%, S&P 500 rising 0.7%, and Nasdaq gaining 0.6%. The core Personal Consumption Expenditures index showed monthly deceleration, although inflation remains above the Fed’s 2% target. Concerns over a potential government shutdown and tariff threats from Trump weighed on global markets, while Novo Nordisk’s shares plummeted 20% following disappointing trial results for its obesity drug.
about US stocks rebound as inflation data shows signs of improvementUS Stocks Rebound as Inflation Data Shows Price Deceleration in November
US stocks rebounded on Friday as inflation data indicated a slowdown in price increases for November, with the Dow Jones rising 0.8%, the S&P 500 up 0.7%, and the Nasdaq gaining 0.6%. Despite a previous sell-off due to the Fed’s projections for fewer rate cuts in 2025, the market stabilized amid concerns over a potential government shutdown and tariff threats from Trump against Europe. Notably, Novo Nordisk’s shares plummeted nearly 20% following disappointing trial results for its obesity drug.
about US Stocks Rebound as Inflation Data Shows Price Deceleration in November